Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

CRANBURY, N.J., May 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced financial results for the third quarter ended March 31, 2013. The Company also summarized end-of-Phase 2 discussions with the U.S. Food and Drug Administration (FDA) and next steps for its Phase 3 pivotal registration program for bremelanotide, its product in development as a novel treatment for female sexual dysfunction (FSD). Palatin will hold a conference call and live audio webcast later today.

End-of-Phase 2 Meeting with FDA on Bremelanotide for FSD
In the end-of-Phase 2 meeting with FDA, Palatin reached preliminary agreement on key aspects of the Phase 3 pivotal registration studies, including:

  • FSD patient population
  • Primary and key secondary efficacy endpoints
  • Study design
  • Dose selection
  • Safety monitoring
  • In addition, the FDA agreed with Palatin's position that the blood pressure and heart rate signals of bremelanotide had been adequately characterized during the Phase 2 program. The FDA also agreed with the proposed Phase 3 blood pressure monitoring program, which will consist of standardized methods for in-clinic assessment of blood pressure.

    "We view our positive meeting with the FDA as a major milestone in the development of bremelanotide for FSD. We are pleased to have concurrence from the FDA on the design and selection of efficacy endpoints of our Phase 3 clinical studies," stated Carl Spana, Ph.D., President and CEO of Palatin. "We are also pleased with the FDA's concurrence that the blood pressure monitoring program for our Phase 3 clinical studies only includes standardized methods for in-clinic assessment of blood pressure. We look forward to advancing bremelanotide for FSD towards a suc
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
    2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
    3. Palatin Technologies To Present At The 25th Annual ROTH Conference
    4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
    5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
    6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
    7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
    8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
    9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
    10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/30/2015)... GERMANTOWN, Md. , March 30, 2015  /PRNewswire/ ... a leader in synthetic biology, and Merck Serono, ... Germany , today announced an exclusive ... commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. ... to develop innovative therapies that modulate the immune ...
    (Date:3/30/2015)... , March 30, 2015 ... novel biological drugs to treat cancer, viral infections ... Professor Sir John Bell , the Regius ... of the Office for the Strategic Coordination of ... immediate effect.      (Photo: http://photos.prnewswire.com/prnh/20150330/736483 ...
    (Date:3/30/2015)... MADISON, Wis. , March 30, 2015 ... (TSE: 4901) ("Fujifilm") and Cellular Dynamics International, Inc. (CEO: ... ("CDI"), a leading developer and manufacturer of fully functioning ... announced that the two companies have entered into a ... all-cash tender offer to be followed by a second ...
    (Date:3/29/2015)... IRVING, Texas , March 29, 2015 ... the presentation of important study data showing ... cells in 1,599 gynecologic cancer samples. Using ... tumor profiling service, researchers identified expression of ... gynecologic cancers independent of histology while its ...
    Breaking Biology Technology:Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 2Immunocore Appoints Professor Sir John Bell to its Board of Directors 3Immunocore Appoints Professor Sir John Bell to its Board of Directors 4Immunocore Appoints Professor Sir John Bell to its Board of Directors 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 2Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 3Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 4Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 5Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 6Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 7Fujifilm Holdings to Acquire Cellular Dynamics International, Inc. 8Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 2Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 3Caris Life Sciences' Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies 4
    ... PARIS and PRINCETON, New Jersey, March 5 , ... Early Use of,Plavix(R) by Simplifying Administration in Acute Coronary ... and Bristol-Myers Squibb,Company (NYSE: BMY ) announced today ... of the European Medicines Evaluation Agency,(EMEA) has issued a ...
    ... FREMONT, Calif., March 4 Vermillion, Inc.,(Nasdaq: ... recent,accomplishments across its diagnostic test programs and provided ... achieve over the course of 2008. The,Company also ... year,ended December 31, 2007., "In 2007, Vermillion ...
    ... Board of Directors of,Bristol-Myers Squibb Company (NYSE: BMY ) ... on the $.10 par value Common,Stock of the corporation. The ... of record at the close of business on April 4, ... fifty cents ($0.50),per share on the $2.00 Convertible Preferred Stock ...
    Cached Biology Technology:New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP) 2New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP) 3New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP) 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 2Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 3Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 5Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 6Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 7Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 8Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 9
    (Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
    (Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
    (Date:3/10/2015)... 10, 2015  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing ... wallet has been named the "Number One Best ... Rethink Modern ( http://www.rethinkmodern.com/ ) is a ... home and lifestyle that have a unique function or ...
    Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
    ... has long been used topically in many skin creams ... for the skin. Now, new research just published in ... consuming flavanol-rich cocoa and how it might actually benefit ... certain components in cocoa may actually help improve the ...
    ... vaccines may increase elderly patients' immune response without ... protection against the flu, according to an article ... Internal Medicine, one of the JAMA/Archives journals. , ... for 50 years to prevent flu and its ...
    ... the Stanford University School of Medicine have taken a ... that could eventually be transplanted into living organisms. , ... resident Oscar Abilez, MD, and colleagues have successfully differentiated ... blocks of blood vessels, after placing them in a ...
    Cached Biology News:New study reveals components of cocoa may enhance the appearance of the skin 2High-dose flu vaccines appear to safely boost immunity in elderly 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 3
    Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
    ... HT, 1 kit. Facilitates the simple, phenol-free ... and hard tissue requiring proteinase K digestion.Each ... DNA from 50 preparations of up to ... Synthesis & Purification, Purification and Amplification of ...
    Request Info...
    Ultra-sensitive, non-radioactive measurement of COX-I and COX-II activity...
    Biology Products: